Published in Rheumatology (Oxford) on July 21, 2010
Weight Loss, the Obesity Paradox, and the Risk of Death in Rheumatoid Arthritis. Arthritis Rheumatol (2015) 2.35
Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum (2013) 1.72
Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis (2013) 1.20
A secure distributed logistic regression protocol for the detection of rare adverse drug events. J Am Med Inform Assoc (2012) 1.09
Early remission is associated with improved survival in patients with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis (2013) 0.88
TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits. PLoS One (2015) 0.88
Serum cotinine as a biomarker of tobacco exposure and the association with treatment response in early rheumatoid arthritis. Arthritis Care Res (Hoboken) (2012) 0.84
Determinants of mortality among postmenopausal women in the women's health initiative who report rheumatoid arthritis. Arthritis Rheumatol (2014) 0.82
Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken) (2014) 0.82
The Obesity Epidemic and Consequences for Rheumatoid Arthritis Care. Curr Rheumatol Rep (2016) 0.81
Protein engineering and preclinical development of a GM-CSF receptor antibody for the treatment of rheumatoid arthritis. Br J Pharmacol (2013) 0.81
Predictors of longterm changes in body mass index in rheumatoid arthritis. J Rheumatol (2015) 0.80
Vascular calcifications on hand radiographs in rheumatoid arthritis and associations with autoantibodies, cardiovascular risk factors and mortality. Rheumatology (Oxford) (2015) 0.80
Fibrinogen-specific antibody induces abdominal aortic aneurysm in mice through complement lectin pathway activation. Proc Natl Acad Sci U S A (2013) 0.80
[The safety of biologics : a risk-benefit assessment of treating rheumatoid arthritis with biologics based on registry data on mortality]. Z Rheumatol (2010) 0.78
Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis. Adv Ther (2016) 0.77
Anti-carbamylated protein autoantibodies associated with mortality in Spanish rheumatoid arthritis patients. PLoS One (2017) 0.77
Changes in Body Mass Related to the Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis. Arthritis Rheumatol (2016) 0.76
Clinical patient registry recruitment and retention: a survey of patients in two chronic disease registries. BMC Med Res Methodol (2017) 0.75
Prednisone Use and Risk of Mortality in Patients With Rheumatoid Arthritis: Moderation by Use of Disease-Modifying Antirheumatic Drugs. Arthritis Care Res (Hoboken) (2016) 0.75
Impact of interstitial lung disease on mortality of patients with rheumatoid arthritis. Rheumatol Int (2017) 0.75
A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice? Clin Rheumatol (2017) 0.75
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum (1995) 26.94
Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet (2002) 9.66
The mortality of rheumatoid arthritis. Arthritis Rheum (1994) 6.18
Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum (1983) 5.96
Accuracy and completeness of mortality data in the Department of Veterans Affairs. Popul Health Metr (2006) 4.04
Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol (1997) 3.65
Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes. J Rheumatol (2007) 3.41
Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum (2003) 3.13
Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol (1999) 3.02
Smoking and causes of death among U.S. veterans: 16 years of observation. Public Health Rep (1980) 3.00
Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis (2003) 2.34
Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum (2000) 2.29
The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum (2007) 2.25
Recent improvements in survival in patients with rheumatoid arthritis: better outcomes or different study designs? Arthritis Rheum (2001) 2.09
Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol (2002) 2.01
The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) (2009) 1.99
Taking mortality in rheumatoid arthritis seriously--predictive markers, socioeconomic status and comorbidity. J Rheumatol (1986) 1.98
Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol (2008) 1.97
Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) (2009) 1.79
Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum (2004) 1.67
Post-traumatic stress and associated disorders among Vietnam veterans: the significance of combat exposure and social support. J Trauma Stress (1995) 1.63
Cachexia in rheumatoid arthritis. Int J Cardiol (2002) 1.47
Mortality and predictors of mortality in rheumatoid arthritis--a role for mannose-binding lectin? J Rheumatol (2010) 1.46
Problems due to medication costs among VA and non-VA patients with chronic illnesses. Am J Manag Care (2004) 1.31
Postservice mortality among Vietnam veterans. The Centers for Disease Control Vietnam Experience Study. JAMA (1987) 1.28
Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women's Health Study. Ann Rheum Dis (2002) 1.21
Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis. Arthritis Care Res (Hoboken) (2010) 1.15
The association of race and ethnicity with disease expression in male US veterans with rheumatoid arthritis. J Rheumatol (2007) 1.12
Mortality in patients with rheumatoid arthritis treated with low-dose oral glucocorticoids. A population-based cohort study. J Rheumatol (2006) 1.11
Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis. PLoS One (2009) 1.09
Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis. Arthritis Rheum (2007) 1.06
Anti-CCP antibody and rheumatoid factor concentrations predict greater disease activity in men with rheumatoid arthritis. Ann Rheum Dis (2010) 1.04
The influence of age at symptom onset and length of followup on mortality in patients with recent-onset inflammatory polyarthritis. Arthritis Rheum (2008) 1.04
Rheumatoid cachexia: a complication of rheumatoid arthritis moves into the 21st century. Arthritis Res Ther (2009) 0.99
Mortality ascertainment of women veterans: a comparison of sources of vital status information, 1979-2002. Med Care (2009) 0.91
Causes of death in patients with rheumatoid arthritis from 1971 to 1991 with special reference to autopsy. Clin Rheumatol (2009) 0.87
The role of the Veterans Affairs Medical Centers in patient care, surgical education, research and faculty development. Am J Surg (2005) 0.84
Dual-energy X-ray absorptiometry and evaluation of the osteoporosis self-assessment tool in men with rheumatoid arthritis. J Clin Densitom (2009) 0.80
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum (2011) 6.28
American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) (2010) 4.65
Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum (2004) 4.57
Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum (2002) 4.15
American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis (2011) 4.15
Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther (2009) 3.47
Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) (2012) 3.47
Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes. J Rheumatol (2007) 3.41
Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med (2004) 3.36
Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum (2007) 3.16
Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum (2006) 3.16
Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum (2003) 3.13
Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum (2004) 3.06
Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. Ann Intern Med (2009) 3.03
A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum (2010) 2.88
Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis (2009) 2.74
Effect of body mass index on mortality and clinical status in rheumatoid arthritis. Arthritis Care Res (Hoboken) (2012) 2.70
Retracted EPCA-2: a highly specific serum marker for prostate cancer. Urology (2007) 2.67
Development and validation of the health assessment questionnaire II: a revised version of the health assessment questionnaire. Arthritis Rheum (2004) 2.57
High-pressure distention of the saphenous vein during preparation results in increased markers of inflammation: a potential mechanism for graft failure. Ann Thorac Surg (2011) 2.25
Anemia and renal function in patients with rheumatoid arthritis. J Rheumatol (2006) 2.25
The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns. Arthritis Rheumatol (2014) 2.14
The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum (2007) 2.10
Expanding the definition of clinical differences: from minimally clinically important differences to really important differences. Analyses in 8931 patients with rheumatoid arthritis. J Rheumatol (2005) 2.05
The prevalence and incidence of work disability in rheumatoid arthritis, and the effect of anti-tumor necrosis factor on work disability. J Rheumatol (2007) 1.85
Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2002) 1.84
Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J Rheumatol (2005) 1.81
Antibody responses to Porphyromonas gingivalis (P. gingivalis) in subjects with rheumatoid arthritis and periodontitis. Int Immunopharmacol (2008) 1.79
A delphi exercise to identify characteristic features of gout - opinions from patients and physicians, the first stage in developing new classification criteria. J Rheumatol (2013) 1.77
Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. Arthritis Rheum (2008) 1.73
Fibromyalgia diagnosis: a comparison of clinical, survey, and American College of Rheumatology criteria. Arthritis Rheum (2006) 1.73
Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol (2005) 1.70
Health literacy predicts the discrepancy between patient and provider global assessments of rheumatoid arthritis activity at a public urban rheumatology clinic. J Rheumatol (2010) 1.66
Effects of infertility, pregnancy loss, and patient concerns on family size of women with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2012) 1.65
Work limitations among working persons with rheumatoid arthritis: results, reliability, and validity of the work limitations questionnaire in 836 patients. J Rheumatol (2005) 1.63
Malondialdehyde-acetaldehyde adducts and anti-malondialdehyde-acetaldehyde antibodies in rheumatoid arthritis. Arthritis Rheumatol (2015) 1.58
Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol (2005) 1.56
Association of periodontitis with rheumatoid arthritis: a pilot study. J Periodontol (2010) 1.53
Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice. J Rheumatol (2004) 1.53
Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis. Arthritis Res Ther (2011) 1.53
Steroids for rheumatoid arthritis: the honeymoon revisited (once again). J Rheumatol (2005) 1.52
Porphyromonas gingivalis and disease-related autoantibodies in individuals at increased risk of rheumatoid arthritis. Arthritis Rheum (2012) 1.52
SH2D1A regulates T-dependent humoral autoimmunity. J Exp Med (2004) 1.51
Jaw pain: its prevalence and meaning in patients with rheumatoid arthritis, osteoarthritis, and fibromyalgia. J Rheumatol (2005) 1.51
Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize ra patients with fibromyalgia. J Rheumatol (2004) 1.51
Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus. J Autoimmun (2006) 1.51
Out-of-pocket expenses and their burden in patients with rheumatoid arthritis. Arthritis Rheum (2009) 1.49
Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients' treatment choices. Arthritis Rheum (2007) 1.44
The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. Arthritis Rheum (2008) 1.44
Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis. J Bone Miner Res (2013) 1.44
Sleep disturbance in patients with rheumatoid arthritis: evaluation by medical outcomes study and visual analog sleep scales. J Rheumatol (2006) 1.43
Patient perception of the burden of weight gain and blood pressure increase among RA patients using celecoxib, rofecoxib, and non-specific NSAIDs. J Clin Rheumatol (2003) 1.42
Periodontitis and Porphyromonas gingivalis in patients with rheumatoid arthritis. Arthritis Rheumatol (2014) 1.40
The impact of obesity and adiposity on inflammatory markers in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) (2017) 1.38
Propulsion patterns and pushrim biomechanics in manual wheelchair propulsion. Arch Phys Med Rehabil (2002) 1.35
Chronic conditions and health problems in rheumatic diseases: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, systemic lupus erythematosus, and fibromyalgia. J Rheumatol (2010) 1.34
The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes. Arthritis Rheum (2005) 1.31
Predicting depression in rheumatoid arthritis: the signal importance of pain extent and fatigue, and comorbidity. Arthritis Rheum (2009) 1.31
Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. Arthritis Rheum (2008) 1.28
A composite disease activity scale for clinical practice, observational studies, and clinical trials: the patient activity scale (PAS/PAS-II). J Rheumatol (2005) 1.28
Limited health literacy is a common finding in a public health hospital's rheumatology clinic and is predictive of disease severity. J Clin Rheumatol (2011) 1.27
Assessment of pain in rheumatoid arthritis: minimal clinically significant difference, predictors, and the effect of anti-tumor necrosis factor therapy. J Rheumatol (2007) 1.27
Remission of rheumatoid arthritis in clinical practice: application of the American College of Rheumatology/European League Against Rheumatism 2011 remission criteria. Arthritis Rheum (2011) 1.27
Improving the pharmacologic management of pain in older adults: identifying the research gaps and methods to address them. Pain Med (2011) 1.25
Prevalence of vitamin D insufficiency/deficiency in rheumatoid arthritis and associations with disease severity and activity. J Rheumatol (2010) 1.24
Immune responses to methamphetamine by active immunization with peptide-based, molecular adjuvant-containing vaccines. Vaccine (2009) 1.23
Post-traumatic growth following spinal cord injury. J Spinal Cord Med (2013) 1.23
The National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank. Rheumatology (Oxford) (2010) 1.21
Do we need core sets of fibromyalgia domains? The assessment of fibromyalgia (and other rheumatic disorders) in clinical practice. J Rheumatol (2011) 1.17
Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice. Arthritis Care Res (Hoboken) (2011) 1.16
Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant. Int Immunopharmacol (2003) 1.16
Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology (Oxford) (2011) 1.14
Shoulder kinematics and kinetics during two speeds of wheelchair propulsion. J Rehabil Res Dev (2007) 1.13
The association of race and ethnicity with disease expression in male US veterans with rheumatoid arthritis. J Rheumatol (2007) 1.12
Synthesis and evaluation of a well-defined HPMA copolymer-dexamethasone conjugate for effective treatment of rheumatoid arthritis. Pharm Res (2008) 1.11
Gout-related health care utilization in US emergency departments, 2006 through 2008. Arthritis Care Res (Hoboken) (2013) 1.10
Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis. Arthritis Rheumatol (2014) 1.10
Early detection and treatment of wear particle-induced inflammation and bone loss in a mouse calvarial osteolysis model using HPMA copolymer conjugates. Mol Pharm (2011) 1.10